

Bangladesh Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Bangladesh			
2. Grant number: 1418-BGD-25b-X / 1418-BGD-25b-Y / 14-BGD-08h-Y			
3. Date of Decision Letter: 19 April 2017			
4. Date of the Partnership Framework Agreement: 24 June 2013			
5. Programme title: NVS, IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID			
8. Programme duration²: 2015 - 2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
<i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2016	2017	Total ³
Programme Budget (US\$)	9,826,310	2,425,500	12,251,810
10. Vaccine introduction grant: US\$ 2,498,000 was disbursed on 14 Aug 2014. The use of residual funds from the IPV VIG (Decision Letter dated 30 June 2014) to support the switch to fractional dose IPV is subject to Gavi approval of the reprogrammed IPV VIG budget.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2015-2016	2017	
Number of IPV vaccines doses		1,240,700	
Annual Amounts (US\$)	9,826,310	2,425,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2017.

⁴ This is the amount that Gavi has approved.

13. Self-procurement: Not applicable	
14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Bangladesh is encouraged to contribute to vaccine and/or supply costs for IPV.	
15. Operational support for campaigns: Not applicable	
16. Additional reporting requirements:	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic performance.	As per agreed schedule for each indicator in the Grant Performance Framework
In accordance with applicable Gavi processes, Country shall report on financial performance through periodic financial reports on all cash support.	Periodic 6 monthly financial report with variance analysis due 45 days after period end. Detailed budget activity reporting Asset listings
In accordance with applicable Gavi processes, Country shall report on financial performance through annual financial reports on all cash support.	Annual financial report with variance analysis due 3 months following end of Country's fiscal year.
External Audit Report	6 months after end of grant
In accordance with applicable Gavi guidelines, Country shall report on general programme information, including Immunisation Financing and Expenditure, and Data Quality Reports	As per Guidelines on Reporting and Renewal
17. Financial clarifications: Country shall provide the following clarifications to Gavi*: Not applicable	
18. Other conditions: Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the presentation and actual number of doses shipped may differ from what is specified in this Decision Letter. In order to mitigate these circumstances, the country is strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.	

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
19 April 2017